{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T16:18:25Z","timestamp":1788279505805,"version":"build-2803163510"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":106,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["POC PNRR TOINPROVE\/2023"],"award-info":[{"award-number":["POC PNRR TOINPROVE\/2023"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["PE00000007"],"award-info":[{"award-number":["PE00000007"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Research in Microbial Sciences"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.crmicr.2026.100599","type":"journal-article","created":{"date-parts":[[2026,4,19]],"date-time":"2026-04-19T14:57:12Z","timestamp":1776610632000},"page":"100599","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Targeting the US21 viroporin of human cytomegalovirus by calcium channel blockers as a new antiviral strategy"],"prefix":"10.1016","volume":"10","author":[{"given":"Giulia","family":"Sibille","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Loggia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluca","family":"Catucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Gilardino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Fiorio","family":"Pla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna Di","family":"Nardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Munaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianfranco","family":"Gilardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgio","family":"Gribaudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4256-5774","authenticated-orcid":false,"given":"Anna","family":"Luganini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"e1","key":"10.1016\/j.crmicr.2026.100599_bib0001","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/S0033583524000192","article-title":"Viroporins: discovery, methods of study, and mechanisms of host-membrane permeabilization","volume":"58","author":"Alcaraz","year":"2025","journal-title":"Q. Rev. Biophys."},{"key":"10.1016\/j.crmicr.2026.100599_bib0002","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0922-4106(89)90004-7","article-title":"(+)-Niguldipine binds with very high affinity to Ca2+ channels and to a subtype of alpha 1-adrenoceptors","volume":"172","author":"Boer","year":"1989","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.biocel.2022.106185","article-title":"Viroporins: structure, function, and their role in the life cycle of SARS-CoV-2","volume":"145","author":"Breitinger","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"15","key":"10.1016\/j.crmicr.2026.100599_bib0004","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.02392-16","article-title":"Congenital Human Cytomegalovirus infection and the enigma of maternal immunity","volume":"91","author":"Britt","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0005","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.antiviral.2018.09.003","article-title":"New therapies for human cytomegalovirus infections","volume":"159","author":"Britt","year":"2018","journal-title":"Antiviral Res."},{"key":"10.1016\/j.crmicr.2026.100599_bib0006","doi-asserted-by":"crossref","first-page":"6875","DOI":"10.1128\/JVI.06310-11","article-title":"The US16 gene of human cytomegalovirus is required for efficient viral infection of endothelial and epithelial cells","volume":"86","author":"Bronzini","year":"2012","journal-title":"J. Virol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0007","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1007\/s40262-024-01437-5","article-title":"Drug\u2013drug interaction management with the novel anti-cytomegalovirus agents letermovir and maribavir: guidance for clinicians","volume":"63","author":"Burger","year":"2024","journal-title":"Clin. Pharmacokinet."},{"issue":"21","key":"10.1016\/j.crmicr.2026.100599_bib0008","doi-asserted-by":"crossref","first-page":"11092","DOI":"10.1128\/JVI.01141-15","article-title":"Inactivation of the Human Cytomegalovirus US20 gene hampers productive viral replication in endothelial cells","volume":"89","author":"Cavaletto","year":"2015","journal-title":"J. Virol."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100599_bib0009","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.jpha.2015.09.001","article-title":"Determination of lercanidipine in human plasma by an improved UPLC-MS\/MS method for a bioequivalence study","volume":"6","author":"Chaudhary","year":"2016","journal-title":"J. Pharm. Anal."},{"issue":"15","key":"10.1016\/j.crmicr.2026.100599_bib0010","article-title":"Biologics for generalized pustular psoriasis: a systematic review and single-arm meta-analysis","volume":"14","author":"Chen","year":"2024","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100599_bib0011","doi-asserted-by":"crossref","first-page":"94","DOI":"10.3390\/cells9010094","article-title":"Host calcium channels and pumps in viral infections","volume":"9","author":"Chen","year":"2019","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.crmicr.2026.100599_bib0012","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000427","article-title":"Cytomegalovirus infection causes an increase of arterial blood pressure","volume":"5","author":"Cheng","year":"2009","journal-title":"PLoS. Pathog."},{"key":"10.1016\/j.crmicr.2026.100599_bib0013","series-title":"CompuSyn for Drug Combinations: PC Software and User\u2019s Guide \u2013 a Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations, and the Determination of IC50, ED50 and LD50 Values","author":"Chou","year":"2005"},{"key":"10.1016\/j.crmicr.2026.100599_bib0014","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1124\/pr.58.3.10","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.crmicr.2026.100599_bib0015","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou\u2013Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res."},{"issue":"22","key":"10.1016\/j.crmicr.2026.100599_bib0016","doi-asserted-by":"crossref","first-page":"4450","DOI":"10.1111\/bph.17317","article-title":"Advancing the field of viroporins-structure, function and pharmacology: IUPHAR Review 39","author":"Devantier","year":"2024","journal-title":"Br. J. Pharmacol."},{"issue":"6","key":"10.1016\/j.crmicr.2026.100599_bib0017","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1097\/00132580-200111000-00008","article-title":"Lercanidipine: a novel dihydropyridine calcium-channel blocker","author":"Epstein","year":"2001","journal-title":"Heart. Dis."},{"key":"10.1016\/j.crmicr.2026.100599_bib0018","doi-asserted-by":"crossref","first-page":"e5157","DOI":"10.1002\/pro.5157","article-title":"Evaluating the potential of non-immunosuppressive cyclosporin analogs for targeting toxoplasma gondii cyclophilin: insights from structural studies","volume":"33","author":"Favretto","year":"2024","journal-title":"Protein Sci."},{"issue":"Suppl 1","key":"10.1016\/j.crmicr.2026.100599_bib0019","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00129784-200707001-00003","article-title":"Calcium channel blockers: differences between subclasses","volume":"7","author":"Frishman","year":"2007","journal-title":"Am. J. Cardiovasc. Drugs"},{"issue":"1","key":"10.1016\/j.crmicr.2026.100599_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.gene.2016.08.020","article-title":"Human flavin containing monooxygenase 3: structural mapping of gene polymorphisms and insights into molecular basis of drug binding","volume":"593","author":"Gao","year":"2016","journal-title":"Gene"},{"key":"10.1016\/j.crmicr.2026.100599_bib0021","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2017.00286","article-title":"Discovery and development of calcium channel blockers","volume":"8","author":"Godfraind","year":"2017","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0022","article-title":"Anti-CMV therapy, what next?","volume":"14","author":"Gourin","year":"2023","journal-title":"A systematic review. Front Microbiol."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100599_bib0023","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/path.4437","article-title":"The pathogenesis of human cytomegalovirus","volume":"235","author":"Griffiths","year":"2015","journal-title":"J. Pathol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104732","article-title":"The direct and indirect consequences of cytomegalovirus infection and potential benefits of vaccination","volume":"176","author":"Griffiths","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.crmicr.2026.100599_bib0025","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1038\/nm.2497","article-title":"The calcineurin inhibitor tacrolimus activates the renal sodium chloride cotransporter to cause hypertension","volume":"17","author":"Hoorn","year":"2011","journal-title":"Nat. Med."},{"key":"10.1016\/j.crmicr.2026.100599_bib0026","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5301\/jn.5000174","article-title":"Pathogenesis of calcineurin inhibitor-induced hypertension","volume":"25","author":"Hoorn","year":"2012","journal-title":"J. Nephrol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0027","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","article-title":"Highly accurate protein structure prediction with AlphaFold","volume":"596","author":"Jumper","year":"2021","journal-title":"Nat"},{"issue":"6","key":"10.1016\/j.crmicr.2026.100599_bib0028","doi-asserted-by":"crossref","first-page":"416","DOI":"10.2165\/00003088-199222060-00002","article-title":"Clinical pharmacokinetics of calcium antagonists. An update","volume":"22","author":"Kelly","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.crmicr.2026.100599_bib0029","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1093\/bioinformatics\/btu426","article-title":"YASARA view - molecular graphics for all devices - from smartphones to workstations","volume":"30","author":"Krieger","year":"2014","journal-title":"Bioinformatics."},{"issue":"8","key":"10.1016\/j.crmicr.2026.100599_bib0030","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.3390\/v14081750","article-title":"Searching for blockers of dengue and West Nile Virus viroporins","volume":"14","author":"Lahiri","year":"2022","journal-title":"Viruses."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100599_bib0031","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12916-025-04022-0","article-title":"Cilnidipine exerts antiviral effects in vitro and in vivo by inhibiting the internalization and fusion of influenza A virus","volume":"23","author":"Li","year":"2025","journal-title":"BMC. Med."},{"key":"10.1016\/j.crmicr.2026.100599_bib0032","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpba.2014.11.001","article-title":"Determination of efonidipine in human plasma by LC-MS\/MS for pharmacokinetic applications","volume":"103","author":"Liu","year":"2015","journal-title":"J. Pharm. Biomed. Anal."},{"key":"10.1016\/j.crmicr.2026.100599_bib0033","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1128\/AAC.00987-07","article-title":"Phosphorothioate-modified oligodeoxynucleotides inhibit human cytomegalovirus replication by blocking virus entry","volume":"52","author":"Luganini","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"issue":"11","key":"10.1016\/j.crmicr.2026.100599_bib0034","doi-asserted-by":"crossref","first-page":"e00205","DOI":"10.1128\/JVI.00205-17","article-title":"Loss of the Human Cytomegalovirus US16 protein abrogates virus entry into endothelial and epithelial cells by reducing the virion content of the pentamer","volume":"91","author":"Luganini","year":"2017","journal-title":"J. Virol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0035","doi-asserted-by":"crossref","first-page":"E12370","DOI":"10.1073\/pnas.1813183115","article-title":"Human cytomegalovirus US21 protein is a viroporin that modulates calcium homeostasis and protects cells against apoptosis","volume":"115","author":"Luganini","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"10.1016\/j.crmicr.2026.100599_bib0036","article-title":"The US21 viroporin of human cytomegalovirus stimulates cell migration and adhesion","volume":"14","author":"Luganini","year":"2023","journal-title":"mBio"},{"key":"10.1016\/j.crmicr.2026.100599_bib0037","series-title":"StatPearls [Internet]","article-title":"Calcium channel blockers","author":"McKeever","year":"2024"},{"key":"10.1016\/j.crmicr.2026.100599_bib0038","series-title":"Fields Virology","first-page":"2701","article-title":"Cytomegalovirus","author":"Mocarski","year":"2007"},{"key":"10.1016\/j.crmicr.2026.100599_bib0039","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1002\/(SICI)1096-987X(19981115)19:14<1639::AID-JCC10>3.0.CO;2-B","article-title":"Automated docking using a lamarckian genetic algorithm and an empirical binding free energy function","volume":"19","author":"Morris","year":"1998","journal-title":"J. Comput. Chem."},{"issue":"16","key":"10.1016\/j.crmicr.2026.100599_bib0040","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.crmicr.2026.100599_bib0041","doi-asserted-by":"crossref","first-page":"14976","DOI":"10.1073\/pnas.2136652100","article-title":"Coding potential of laboratory and clinical strains of human cytomegalovirus","volume":"100","author":"Murphy","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"8","key":"10.1016\/j.crmicr.2026.100599_bib0042","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/nrmicro2820","article-title":"Viroporins: structure and biological functions","volume":"10","author":"Nieva","year":"2012","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2025.107863","article-title":"Viroporins beyond pathogenesis: ion channel properties as the key to unlocking a neglected antiviral target","volume":"219","author":"Peng","year":"2025","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.crmicr.2026.100599_bib0044","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.antiviral.2019.01.011","article-title":"Clinical development of letermovir and maribavir: overview of human cytomegalovirus drug resistance","author":"Piret","year":"2019","journal-title":"Antiviral Res."},{"issue":"9","key":"10.1016\/j.crmicr.2026.100599_bib0045","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01038-25","article-title":"Viroporins: emerging viral infection mechanisms and therapeutic targets","volume":"99","author":"Qu","year":"2025","journal-title":"J. Virol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0046","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1099\/0022-1317-82-6-1429","article-title":"In vitro selection of human cytomegalovirus variants unable to transfer virus and virus products from infected cells to polymorphonuclear leukocytes and to grow in endothelial cells","volume":"82","author":"Revello","year":"2001","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0047","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1128\/JVI.80.2.710-722.2006","article-title":"Human cytomegalovirus entry into epithelial and endothelial cells depends on genes UL128 to UL150 and occurs by endocytosis and low-pH fusion","volume":"80","author":"Ryckman","year":"2006","journal-title":"J. Virol."},{"issue":"6225","key":"10.1016\/j.crmicr.2026.100599_bib0048","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1126\/science.1258758","article-title":"Ebola virus. Two-pore channels control Ebola virus host cell entry and are drug targets for disease treatment","volume":"347","author":"Sakurai","year":"2015","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.crmicr.2026.100599_bib0049","first-page":"451","article-title":"Clinical pharmacokinetics of calcium antagonists","volume":"57","author":"Sesin","year":"1997","journal-title":"Medicina (B Aires)"},{"issue":"10","key":"10.1016\/j.crmicr.2026.100599_bib0050","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/ardp.19943271002","article-title":"Drug membrane interaction and the importance for drug transport, distribution, accumulation, efficacy and resistance","volume":"327","author":"Seydel","year":"1994","journal-title":"Arch. Pharm. (Weinheim)"},{"issue":"9","key":"10.1016\/j.crmicr.2026.100599_bib0051","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.curtheres.2003.11.004","article-title":"Effects of efonidipine, an l- and T-type dual calcium channel blocker, on heart rate and blood pressure in patients with mild to severe hypertension: an uncontrolled, open-label pilot study","volume":"64","author":"Shimizu","year":"2003","journal-title":"Curr. Ther. Res. Clin. Exp."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100599_bib0052","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1001\/archopht.116.2.178","article-title":"Clinical failure of CMV retinitis with intravitreal cidofovir is associated with antiviral resistance","volume":"116","author":"Smith","year":"1998","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.crmicr.2026.100599_bib0053","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"issue":"2","key":"10.1016\/j.crmicr.2026.100599_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1010343","article-title":"Diltiazem inhibits SARS-CoV-2 cell attachment and internalization and decreases the viral infection in mouse lung","volume":"18","author":"Wang","year":"2022","journal-title":"PLoS. Pathog."},{"issue":"1","key":"10.1016\/j.crmicr.2026.100599_bib0055","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1007\/s10822-025-00643-y","article-title":"Computational exploration and molecular dynamics simulations for investigating the potential inhibitory mechanism of amantadine on the ion channel activity of bovine viral diarrhea virus p7","volume":"39","author":"Wang","year":"2025","journal-title":"J. Comput. Aided Mol. Des."},{"issue":"23","key":"10.1016\/j.crmicr.2026.100599_bib0056","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.2165\/00003495-200363230-00004","article-title":"Azelnidipine","volume":"63","author":"Wellington","year":"2003","journal-title":"Drugs."},{"key":"10.1016\/j.crmicr.2026.100599_bib0057","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4629392","article-title":"Identification of potential WSB1 inhibitors by AlphaFold modeling, virtual screening, and molecular dynamics simulation studies","volume":"2022","author":"Weng","year":"2022","journal-title":"Evid. Based Complement. Alternat. Med."}],"container-title":["Current Research in Microbial Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517426000544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666517426000544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T15:31:25Z","timestamp":1788276685000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666517426000544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":57,"alternative-id":["S2666517426000544"],"URL":"https:\/\/doi.org\/10.1016\/j.crmicr.2026.100599","relation":{},"ISSN":["2666-5174"],"issn-type":[{"value":"2666-5174","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting the US21 viroporin of human cytomegalovirus by calcium channel blockers as a new antiviral strategy","name":"articletitle","label":"Article Title"},{"value":"Current Research in Microbial Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.crmicr.2026.100599","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100599"}}